{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:19:10Z","timestamp":1788538750930,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470179"],"award-info":[{"award-number":["82470179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2024C03158"],"award-info":[{"award-number":["2024C03158"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Relapsed\/refractory (r\/r) angioimmunoblastic T\u2010cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) &lt;\u20096\u2009months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy\u2010free regimen in this patient population. This single\u2010arm, multicenter, prospective Phase II trial enrolled adult patients with r\/r AITL. Patients received rituximab (375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    intravenously on Day 1), lenalidomide (15\u2009mg orally on Days 1\u201321), and chidamide (30\u2009mg orally twice weekly) in 28\u2010day\u2009cycles for up to 6 cycles. The primary endpoint was progression\u2010free survival (PFS). Secondary endpoints included the overall response rate (ORR), OS, duration of response (DoR), and safety. In total, 28 patients were enrolled between August 2019 and June 2024. The median age was 64\u2009years (range, 44\u201370), and 71.4% had refractory disease. The ORR was 71.4% (complete remission: 32.1%), median PFS was 5.5\u2009months (95% confidence interval [CI], 3.5\u20137.6), median OS was 17.6\u2009months (95% CI, 10.3\u201324.8), and median DoR among responders was 10.7\u2009months (95% CI, 2.7\u201316.0). Notably, 50% of patients with clonal Ig heavy\u2010 or light\u2010chain rearrangements achieved PFS &gt;\u200916\u2009months. All nine patients with baseline serum EBV\u2010DNA positivity converted to undetectable levels after two cycles. No Grade 5 adverse events or venous thromboembolic events occurred. The most common hematological adverse events per cycle were leukopenia (14.3%), thrombocytopenia (12.4%), and neutropenia (11.4%). Overall, the RLC regimen induced clinically meaningful anti\u2010tumor activity with manageable toxicity in patients with r\/r AITL.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/trial.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04319601\">NCT04319601<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1002\/ajh.70366","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:35:26Z","timestamp":1778650526000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>RCLARITY<\/scp>\n                    : A Prospective Phase\n                    <scp>II<\/scp>\n                    Study of Rituximab Combined With Lenalidomide and Chidamide (\n                    <scp>RLC<\/scp>\n                    ) for the Treatment of Relapsed\/Refractory Angioimmunoblastic T\u2010Cell Lymphoma"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5976-7562","authenticated-orcid":false,"given":"Cong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3920-5785","authenticated-orcid":false,"given":"Tao","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2526-0797","authenticated-orcid":false,"given":"Xiyue","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3514-981X","authenticated-orcid":false,"given":"Jialiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-0941","authenticated-orcid":false,"given":"Xiu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pathology Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7970-108X","authenticated-orcid":false,"given":"Zhilu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Tongde Hospital of Zhejiang Province  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7370-7947","authenticated-orcid":false,"given":"Xiang","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Jinhua Hospital, Zhejiang University School of Medicine  Jinhua Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9884-9894","authenticated-orcid":false,"given":"Haifeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4592-850X","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1535-7338","authenticated-orcid":false,"given":"Shuailing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-2812","authenticated-orcid":false,"given":"Shuiyun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-3734","authenticated-orcid":false,"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03832-5"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010387"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060456"},{"key":"e_1_2_12_6_1","unstructured":"N.Sansone M.Hema Sundar A.Halwani et\u00a0al. \u201cT\u2010Cell Lymphomas \u201dNCCN Guidelines Version 1.2026 2025 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t\u2010cell.pdf."},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.158428"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0190-8"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105696"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280996"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(10)70004-7"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2016.1219820"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009767"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022788"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2210-0"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015451"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.03.023"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06620.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06725.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.061507"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.008"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:46:23Z","timestamp":1788536783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":24,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ajh.70366"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70366","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"2026-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}